Morepen Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 8:50 am

Competitors of Morepen Laboratories Ltd

All Competitor Stocks of Morepen Laboratories Ltd

Quarterly Result

Last Updated: August 20, 2025, 6:50 am

Below is a detailed analysis of the quarterly data for Morepen Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 425.00 Cr.. The value appears to be declining and may need further review. It has decreased from 466.00 Cr. (Mar 2025) to 425.00 Cr., marking a decrease of 41.00 Cr..
• For Expenses, as of Jun 2025, the value is 401.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 424.00 Cr. (Mar 2025) to 401.00 Cr., marking a decrease of 23.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 18.00 Cr..
• For OPM %, as of Jun 2025, the value is 6.00%. The value appears to be declining and may need further review. It has decreased from 9.00% (Mar 2025) to 6.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 7.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 10.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 26.00%, marking an increase of 5.00%.
• For Net Profit, as of Jun 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 9.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.20. The value appears to be declining and may need further review. It has decreased from 0.37 (Mar 2025) to 0.20, marking a decrease of 0.17.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:50 am

Balance Sheet

Last Updated: May 13, 2025, 3:05 pm

Below is a detailed analysis of the balance sheet data for Morepen Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 8.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,047.00 Cr.. The value appears strong and on an upward trend. It has increased from 745.00 Cr. (Mar 2024) to 1,047.00 Cr., marking an increase of 302.00 Cr..
• For Borrowings, as of Mar 2025, the value is 105.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 29.00 Cr. (Mar 2024) to 105.00 Cr., marking an increase of 76.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 517.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 417.00 Cr. (Mar 2024) to 517.00 Cr., marking an increase of 100.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,778.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,293.00 Cr. (Mar 2024) to 1,778.00 Cr., marking an increase of 485.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 489.00 Cr.. The value appears strong and on an upward trend. It has increased from 307.00 Cr. (Mar 2024) to 489.00 Cr., marking an increase of 182.00 Cr..
• For CWIP, as of Mar 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2024) to 28.00 Cr., marking an increase of 4.00 Cr..
• For Investments, as of Mar 2025, the value is 85.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 85.00 Cr., marking an increase of 84.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,176.00 Cr.. The value appears strong and on an upward trend. It has increased from 960.00 Cr. (Mar 2024) to 1,176.00 Cr., marking an increase of 216.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,778.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,293.00 Cr. (Mar 2024) to 1,778.00 Cr., marking an increase of 485.00 Cr..

Notably, the Reserves (1,047.00 Cr.) exceed the Borrowings (105.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Morepen Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
• For Diluted EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
• For Cash EPS (Rs.), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 3. It has increased from 2.54 (Mar 24) to 2.68, marking an increase of 0.14.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 33.06. It has decreased from 33.07 (Mar 24) to 33.06, marking a decrease of 0.01.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 3.51. This value is within the healthy range. It has increased from 3.38 (Mar 24) to 3.51, marking an increase of 0.13.
• For PBIT / Share (Rs.), as of Mar 25, the value is 2.98. This value is within the healthy range. It has increased from 2.72 (Mar 24) to 2.98, marking an increase of 0.26.
• For PBT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 2.65 (Mar 24) to 2.83, marking an increase of 0.18.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.15, marking an increase of 0.26.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 2.15, marking an increase of 0.27.
• For PBDIT Margin (%), as of Mar 25, the value is 10.62. This value is within the healthy range. It has increased from 10.21 (Mar 24) to 10.62, marking an increase of 0.41.
• For PBIT Margin (%), as of Mar 25, the value is 9.02. This value is below the healthy minimum of 10. It has increased from 8.23 (Mar 24) to 9.02, marking an increase of 0.79.
• For PBT Margin (%), as of Mar 25, the value is 8.56. This value is below the healthy minimum of 10. It has increased from 8.01 (Mar 24) to 8.56, marking an increase of 0.55.
• For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 6.51, marking an increase of 0.80.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from 5.68 (Mar 24) to 6.51, marking an increase of 0.83.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.20. This value is below the healthy minimum of 15. It has decreased from 11.34 (Mar 24) to 10.20, marking a decrease of 1.14.
• For Return on Capital Employeed (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has decreased from 15.61 (Mar 24) to 12.79, marking a decrease of 2.82.
• For Return On Assets (%), as of Mar 25, the value is 6.63. This value is within the healthy range. It has decreased from 7.43 (Mar 24) to 6.63, marking a decrease of 0.80.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 1.41 (Mar 24) to 1.18, marking a decrease of 0.23.
• For Current Ratio (X), as of Mar 25, the value is 2.32. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.32, marking an increase of 0.11.
• For Quick Ratio (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 1.72, marking an increase of 0.13.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.60. This value is within the healthy range. It has increased from 3.70 (Mar 24) to 6.60, marking an increase of 2.90.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 46.52 (Mar 24) to 23.07, marking a decrease of 23.45.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 15.15. This value is within the healthy range. It has decreased from 27.04 (Mar 24) to 15.15, marking a decrease of 11.89.
• For Enterprise Value (Cr.), as of Mar 25, the value is 2,682.56. It has increased from 2,126.72 (Mar 24) to 2,682.56, marking an increase of 555.84.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.48, marking an increase of 0.22.
• For EV / EBITDA (X), as of Mar 25, the value is 13.94. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.94, marking an increase of 1.62.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
• For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 2.27, marking a decrease of 0.27.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness